FDMT — 4D Molecular Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $611.35m
- $306.28m
- $0.04m
- 55
- 12
- 77
- 46
Annual cashflow statement for 4D Molecular Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -56.7 | -71.3 | -107 | -101 | -161 |
| Depreciation | |||||
| Non-Cash Items | 5.05 | 16.2 | 19.7 | 20.2 | 21.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.711 | -15.5 | -1.34 | 0.63 | 0.537 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -50.9 | -69.1 | -86.7 | -75.8 | -135 |
| Capital Expenditures | -1 | -9.11 | -11.5 | -2.77 | -3.79 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -164 | -5.51 | 118 | -299 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1 | -173 | -17.1 | 116 | -302 |
| Financing Cash Flow Items | — | — | -0.468 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 279 | 118 | 3.08 | 157 | 337 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 227 | -124 | -101 | 197 | -99.8 |